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ABSTRACT
Background
Type 2 diabetes (T2D) is a multifactorial disease in which environmental triggers interact with
genetic variants in the predisposition to the disease. A number of common variants have been
associated with T2D but our knowledge of their ability to predict T2D prospectively is limited.
Methods and Findings
By using a Cox proportional hazard model, common variants in the PPARG (P12A), CAPN10
(SNP43 and 44), KCNJ11 (E23K), UCP2 ( 866G.A), and IRS1 (G972R) genes were studied for their
ability to predict T2D in 2,293 individuals participating in the Botnia study in Finland. After a
median follow-up of 6 y, 132 (6%) persons developed T2D. The hazard ratio for risk of
developing T2D was 1.7 (95% confidence interval [CI] 1.1–2.7) for the PPARG PP genotype, 1.5
(95% CI 1.0–2.2) for the CAPN10 SNP44 TT genotype, and 2.6 (95% CI 1.5–4.5) for the
combination of PPARG and CAPN10 risk genotypes. In individuals with fasting plasma glucose  
5.6 mmol/l and body mass index   30 kg/m
2, the hazard ratio increased to 21.2 (95% CI 8.7–
51.4) for the combination of the PPARG PP and CAPN10 SNP43/44 GG/TT genotypes as
compared to those with the low-risk genotypes with normal fasting plasma glucose and body
mass index , 30 kg/m
2.
Conclusion
We demonstrate in a large prospective study that variants in the PPARG and CAPN10 genes
predict future T2D. Genetic testing might become a future approach to identify individuals at
risk of developing T2D.
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Type 2 diabetes (T2D) is a multifactorial disease in which
environmental triggers interact with genetic variants in the
predisposition to the disease [1]. T2D is characterized by
impaired insulin secretion and insulin action in target tissues
such as muscle and liver [2]. Many patients with a genetic
predisposition to T2D also have a predisposition to weight
gain, and obesity is a strong risk factor for T2D [3].
Although several candidate genes have been associated
with T2D [4–7], many ﬁndings have been difﬁcult to replicate.
The list of genes with support in extensive meta-analyses is
relatively short, including genes encoding for PPARG, calpain
10, Kir 6.2, and insulin receptor substrate 1 (IRS1) [8]. The
PPARG P12A polymorphism is associated with enhanced
insulin sensitivity and protects against T2D [4,9–11].
Although the individual risk reduction for carriers of the
rare A allele is only 15%, the population attributable risk of
the common allele is about 25%. Two intronic single
nucleotide polymorphisms (SNPs) (43 and 44) in the gene
encoding for the cystein protease calpain 10 (CAPN10) confer
increased susceptibility to insulin resistance and T2D [12–15].
The ATP-sensitive potassium channel Kir 6.2 (KCNJ11) forms
together with the sulfonylurea receptor SUR1 (ABCC8), an
octamer protein that regulates transmembrane potential and
thereby glucose-stimulated insulin secretion in pancreatic b-
cells. A E23K polymorphism in KCNJ11 has been associated
with T2D [16–18]. Carriers of a G972R polymorphism in the
IRS1 gene (IRS1) have been shown to have reduced insulin
content in pancreatic islets [19]. Although the meta-analyses
suggested a role for the G972R polymorphism in T2D
[8,20,21], two recent large case-control studies failed to
replicate this association [22,23].
In addition to the genes listed above, we considered it
worthwhile to also include the uncoupling protein 2 gene
(UCP2) in the analysis because some studies have associated a
polymorphism in the promoter of the gene (UCP2 866G.A)
with increased risk of T2D and impaired insulin secretion
[24–27], whereas other studies have reported reduced risk of
T2D [28]. Increased expression of UCP2 in pancreatic islets is
associated with increased uncoupling and thereby decreased
ATP production required for insulin secretion [29].
In this study, we tested variants in a number of candidate
genes for T2D for their ability to predict diabetes in 2,293
individuals without diabetes participating in the Botnia
prospective study in western Finland.
Methods
Study Participants
The Botnia study is a family-based study aiming to identify
genes increasing susceptibility to T2D [30,31]. Details of the
study cohort and sampling strategy have been presented
earlier [31]. In brief, individuals with T2D from the area of
ﬁve health-care centers in western Finland were invited to
participate, together with their family members [31]. An oral
glucose tolerance test (OGTT) was performed for all
participants aged 18–70 y who had fasting plasma glucose
concentration (FPG) lower than 11 mmol/l. Participants
without diabetes, either family members of T2D patients or
control participants (spouses without ﬁrst or second degree
family history of diabetes), between 18–70 y were offered
prospective visits every 2–3 y. During the study period (which
started in 1990 and was closed for this analysis in 2002), 1,869
relatives of T2D patients from 577 extended pedigrees
(approximately three persons per pedigree) and 424 controls
without family history of diabetes participated in at least
OGTTs with a median follow-up of 6 y (range 2–12 y). Of the
participants in both these groups, 1,569 had normal glucose
tolerance and 724 had impaired fasting glucose and/or
impaired glucose tolerance at baseline. Carriers of mutations
causing maturity onset diabetes of the young (n ¼ 20) were
excluded from the present study. Glucose tolerance was
deﬁned according to the current World Health Organization
criteria [32]. All participants gave informed consent, and the
local ethics committee approved the study.
Anthropometric Measurements and Assays
The participants’ weight, height, waist and hip circum-
ference, and blood pressure were measured as previously
reported [30,31]. Body mass index (BMI) was calculated as
weight (in kilograms) divided by height (in meters) squared.
All participants participated in a 75-g OGTT after a 12-h
overnight fast. Fasting blood samples were drawn for the
measurement of high density lipoprotein cholesterol, trigly-
ceride, and free fatty acid concentrations, and at  10, 0, 30,
60, and 120 min for the measurement of plasma glucose and
serum insulin. Insulin resistance was estimated as homeostasis
model assessment index (HOMAIR) using a computer-based
model [33] and b-cell function as the ratio of incremental
insulin to glucose responses during the ﬁrst 30 min of the
OGTT (DI/DG ¼ DI30 min fasting/DG30 min fasting); this index is
also called the insulinogenic index. The disposition index was
used to adjust insulin secretion for the degree of insulin
resistance (insulinogenic index/HOMAIR).
Genotyping
Genotyping of SNPs was performed with a polymerase
chain reaction–restriction fragment length polymorphism
(PCR-RFLP) method and agarose gel electrophoresis for IRS1
G972R, or using the Multiplex SNaPshot kit (Applied
Biosystems, Stockholm, Sweden) for single base pair exten-
sion on ABI 3100 (Applied Biosystems) for CAPN10 SNP43
and 44, or with an allelic discrimination assay-by-design
method on ABI 7900 (Applied Biosystems) for KCNJ11 E23K,
IRS1 G972R, and UCP2  866G.A (Table S1). By randomly
regenotyping 10%–20% of the samples, we achieved con-
cordance rates of 99% for PPARG P12A, CAPN10 SNP44,
KCNJ11 E23K, IRS1 G972R, and UCP2  866G.A, and 98%
for CAPN10 SNP43. All genotypes were in Hardy–Weinberg
equilibrium except CAPN10 SNP44, which showed a moder-
ate deviation from equilibrium (p¼0.035). Genotyping errors
are an unlikely explanation for this deviation from equili-
brium, because in genotyping 1,880 samples of CAPN10
SNP44 using two different methods (allelic discrimination
and single base extension) the concordance rate was 99%.
Statistical Analyses
Variables are presented as median (interquartile range). A
v
2 test was used for comparison of group frequencies.
Survival analysis was used to estimate the effect of genetic
variants (risk and non-risk genotypes deﬁned from previous
studies) on the risk of developing T2D and shown by Kaplan–
Meier survival curves as the distribution of age at onset (the
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Prediction of Type 2 Diabetesproportion of individuals developing T2D at certain age). The
risk of developing T2D was expressed as a hazard function
(the negative slope divided by the survival curve) using an
age-adjusted Cox proportional hazard regression model [34].
The hazard function is the (conditional) probability for the
development of diabetes during a time interval divided by the
length of that time interval, for an individual that is diabetes-
free at the start of the time interval. The relative effect is
presented as the ratio between the hazard functions (hazard
ratio [HR]) of the two groups. HRs quantify the effect size of
both discrete variables (carriers versus non-carriers) and
continuous variables (used in the interaction analysis below
where HR measures the effect of an increase in one unit of
the continuous variable). All survival analyses were stratiﬁed
for gender and adjusted for family history of diabetes and
BMI (when appropriate). The information that an individual
did not or did belong to a nuclear family with at least one
other affected member was coded as zero or one, respectively,
and used as a covariate in the Cox regression analyses. All
survival analyses were performed with a robust variance
estimate to adjust for within family dependence extended to
the large pedigrees. In using a robust variance estimate we
treated each pedigree (instead of each individual) as an
independent entity for calculating the variance of the
estimates.
Expected risk genotypes were deﬁned according to earlier
reports (PP genotype of PPARG, GG genotype of CAPN10
SNP43, TT genotype of CAPN10 SNP44, EK/KK genotypes of
KCNJ11, GR/RR genotypes of IRS1, GG genotype of UCP2).
However, the risk TT genotype of CAPN10 SNP44 was in
opposite direction compared to other studies [13,14] and
selected based upon a previous report from the Botnia study
[15] showing that the combination of the TT genotype of
SNP44 and the GG genotype of SNP43 in CAPN10 was
signiﬁcantly more frequent in patients with T2D than in
control individuals. Therefore, in the present study we refer
to the TT genotype of CAPN10 SNP44 as an at-risk genotype.
Individuals with missing data were excluded from the
analyses.
Analyses of interaction between effect of phenotype (P)
deﬁned as insulin secretion (disposition index) and insulin
action (HOMAIR) and genotype (G) (1¼risk and 0¼non-risk)
on age at onset of T2D were performed using the following
Cox proportional hazards model: h(t) ¼ h0(t)exp(b1P þ b2G þ
b3P*G), in which h(t) is the hazard function and h0(t) is the
baseline hazard function, with b1 and b2 measuring the
univariate effects and b3 measuring the interaction. If there is
an interaction (b3 ne 0), the HR for carriers and non-carriers
of the risk genotype will not be the same. Thus, in different
genotype carriers the HR of T2D associated with x units
increase/decrease in the phenotypic value (P þ x) is HR ¼
exp(b1 þ b3)*x for the risk genotype carriers and HR ¼
exp(b1*x) for the non-risk genotype carriers. A logistic
regression analysis was applied to explore the relationship
between FPG and BMI, with genetic factor (deﬁned as 1¼risk
and 0¼non-risk) as dependent variable and FPG, BMI, and an
interaction term as covariates. All statistical analyses were
performed using Number Crunching Statistical Systems
version 2004 (NCSS, Kaysville, Utah, United States), R
(www.r-project.org), and Stata (StataCorp, College Station,
Texas, United States). Two-sided p-values of less than 0.05
were considered statistically signiﬁcant.
Results
In total, 2,293 persons (1,051 men and 1,242 women) were
included in the study (Table 1). Of them, 1,078 (47%) had
non-normal FPG (  5.6 mmol/l), 280 (12.3%) had BMI   30
kg/m
2, and 160 (7%) had both elevated FPG and BMI   30 kg/
m
2. Of the 2,293 persons included, 132 (6%) (67 men and 65
women; 40 with normal and 92 with abnormal glucose
tolerance) developed diabetes during the follow-up period
of 6 y (converters).
PPARG
The allele and genotype frequencies of the PPARG P12A
polymorphism were similar to those previously reported in
Caucasians [4], with 73.3% of participants carrying the risk
PP genotype (Table 2). Of all individuals who developed T2D,
109 (82.6%) had the PP genotype, which also signiﬁcantly
increased the risk of subsequent T2D (HR 1.7, p ¼ 0.016)
(Figure 1; Table 3). Because we have previously shown that a
family history of diabetes, non-normal FPG (  5.6 mmol/l),
and BMI   30kg/m
2 identify individuals at high risk of T2D
[31], we now tested whether the PPARG risk genotype could
replace family history in this prediction. In fact, the incidence
of T2D was increased in carriers of the PP genotype with
elevated FPG and high BMI as compared with the PA/AA
genotype carriers without any other risk factors (22.9%
versus 1.5%, p , 0.001) (Figure 2). This corresponded to a HR
of 13.5 (95% conﬁdence interval [CI] 4.5–40.7, p , 0.001)
estimated by the Cox model (Table 3). The PPARG genotype
also inﬂuenced the relationship between BMI and FPG; there
was a stronger correlation between BMI and FPG in carriers
of the PPARG PP as compared to the PA/AA genotypes (0.23
versus 0.15, p ¼ 0.041), suggesting a steeper increase in FPG
for any increase in BMI in carriers of the risk genotype.
Furthermore, we observed a signiﬁcant interaction between
the PPARG P12A polymorphism and HOMAIR (p ¼ 0.004),
indicating that with increasing insulin resistance [31] carriers
Table 1. Clinical Characteristics of the Participants at Baseline
Characteristic Value
Number (male/female) 2,293 (1,051/1,242)
NGT/IFG/IGT/IFG or IGT (n) 1,569/271/275/178
Age (y) 45.1 (35.9–55.1)
BMI (kg/m
2) 25.3 (23.0–27.8)
Waist to hip ratio (cm/m
2)
Men 0.94 (0.90–0.98)
Women 0.83 (0.78–0.86)
Waist (cm)
Men 93 (86–99)
Women 81 (74.5–88.0)
FPG (mmol/l) 5.59 (5.20–5.99)
2-h plasma glucose (mmol/l) 6.10 (5.20–7.23)
Fasting serum insulin (pmol/l) 26.7 (19.0–37.3)
2hr S-insulin (pmol/l) 152.6 (91.4–284.4)
HOMAIR 0.5 (0.4–0.7)
Triglycerides (mmol/l) 1.08 (0.82–1.51)
High density lipoprotein cholesterol (mmol/l) 1.35 (1.13–1.59)
FFA (lmol/l) 670.5 (540.8–808)
2-h FFA (lmol/l) 253 (205–312)
Data are given as median [IQR].
FFA, free fatty acid; IFG, impaired fasting glucose; IGT, impaired glucose tolerance; NGT, normal glucose tolerance.
DOI: 10.1371/journal.pmed.0020345.t001
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Prediction of Type 2 DiabetesTable 2. Allele and Genotype Frequencies of the Studied Polymorphisms
Polymorphism Frequency, % (n)
Allele Genotype
PPARG P12A P A PP PA AA
85.5 (3,889) 14.5 (657) 73.3 (1,667) 24.4 (555) 2.3 (51)
CAPN10 SNP43G.AG A G G G A A A
71.1 (3,154) 28.9 (1,284) 50.3 (1,116) 41.5 (922) 8.2 (181)
CAPN10 SNP44T.CT C TT TC CC
78.2 (3,527) 21.8 (983) 62.1 (1,400) 32.2 (727) 5.7 (128)
UCP2  866G.AG A GG GA AA
61.9 (2,742) 38.1 (1,690) 38.0 (842) 47.7 (1,058) 14.3 (316)
IRS1 G972R G R GG GR RR
92.6 (4,034) 7.4 (322) 85.7(1,866) 13.9 (302) 0.4 (10)
KCNJ11 E23K E K EE EK KK
48.9 (2,189) 51.1 (2,285) 23.7 (530) 50.5 (1,129) 25.8 (578)
The high risk alleles/genotypes are shown in bold.
DOI: 10.1371/journal.pmed.0020345.t002
Figure 1. Unadjusted Kaplan–Meier Diabetes-Free Survival Probability Curves
Curves for different carriers of PPARG P12A (PP versus PA/AA), CAPN10 SNP44 (TT versus TC/CC), UCP2  866 G/A (GG versus GA/AA), and the
combination of PPARG and CAPN10 SNP43/44 (PP/GG/TT versus other). y-Axis shows probability of diabetes-free survival time. x-Axis shows follow-up
time in years. The HR of developing T2D in different genotype carriers obtained from Cox proportional hazards regression stratified on sex and adjusted
for age, BMI, and family history of diabetes with robust variance estimate is shown (see also Table 3).
DOI: 10.1371/journal.pmed.0020345.g001
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Prediction of Type 2 Diabetesof the PP genotype had a greater risk of developing T2D than
carriers of the PA/AA genotypes (Figure 3).
The G allele of SNP43 and the C allele of SNP44 were in
strong linkage disequilibrium (D9 ¼ 0.99, p , 0.001). Fifty
percent of the participants had the risk genotype (GG) of
SNP43 and 62.1% had the risk genotype (TT) of SNP44. A
total of 534 (24%) individuals carried both the GG (SNP43)
and the TT (SNP44) genotypes. Seventy (54.3%) of the
converters had the GG (SNP43) genotype, while 91 (70.0%)
had the TT (SNP44) genotype. While SNP43 had no effect on
its own, the SNP44 TT genotype was associated with a
moderately increased risk of T2D (HR 1.5, p ¼ 0.035) (see
Figure 1; Table 3). The incidence of T2D was highest in
individuals carrying both SNP43 (GG) and SNP44 (TT)
genotypes and other risk factors, particularly those with high
BMI, as compared with individuals with low risk genotypes
without any other risk factors (36.7% versus 3.0%, p , 0.001)
(see Figure 2). In the age-adjusted Cox analysis, the
corresponding HR was 13.2 (95% CI 6.0–28.7, p , 0.001)
(Table 3). Also, there was a signiﬁcant interaction between the
GG genotype of SNP43 and HOMAIR, and between the
combination of both risk genotypes (GG/TT) and HOMAIR (p
¼ 0.037 and p ¼ 0.028, respectively), showing that the risk
conferred by worsening of insulin sensitivity [31] increased
more in carriers of these genotypes than in carriers of the low
risk genotypes.
UCP2
Fifty-eight (44.3%) of the converters were homozygous for
the risk genotype (GG) of the UCP2 866G.A variant. The GG
genotype was associated with a modestly increased risk of T2D
(HR 1.4, p ¼ 0.049) (see Figure 1; Table 3). This risk was not
inﬂuenced by BMI and FPG at baseline. However, the GG
genotype was also associated with increased risk of developing
T2D in patients with earlier onset of diabetes (HR 2.0, 95% CI
1.2–3.3, p ¼ 0.0057) (Table 4). Furthermore, the GG genotype
Table 3. Risk of Developing T2D in Different Genotype Carriers of the Studied Polymorphisms
Gene Univariate Effect Multivariate Effect
a
Genotype Converters,
n (%)
Non-Converters,
n (%)
Genotype þ Risk Factors Converters,
n (%)
Non-Converters,
n (%)
PPARG P12A PP 109 (82.6) 1,558 (72.8) PP þ FPG þ BMI 27 (87.1) 91 (25.7)
PA/AA 23 (17.4) 583 (27.2) PA/AA þ none 4 (12.9) 263 (74.4)
HR (95% CI) 1.7 (1.1–2.7) 13.5 (4.5–40.7)
p-Value 0.016
CAPN10 SNP43G.A GG 70 (54.3) 1,046 (50.0) GG þ FPG þ BMI 21 (58.3) 63 (10.9)
GA/AA 59 (45.7) 1,044 (50.0) GA/AA þ none 15 (41.7) 508 (89.1)
HR (95% CI) 1.1 (0.8–1.6) 6.7 (3.6–12.5)
p-Value 0.51
CAPN10 SNP44T.CT T 91 (70.0) 1,309 (61.6) TT þ FPG þ BMI 26 (66.7) 77 (16.1)
TC/CC 39 (30.0) 816 (38.4) TC/CC þ none 13 (33.3) 397 (83.9)
HR (95% CI) 1.5 (1.0–2.2) 8.3 (4.4–15.9)
p-Value 0.035
CAPN10 SNP43/44 GG/TT 42 (33.1) 492 (23.7) GG/TT þ FPG þ BMI 18 (42.9) 31 (3.9)
Other 85 (66.9) 1580 (76.3) Other þ none 24 (57.1) 765 (96.1)
HR (95% CI) 2.1 (1.2–3.5) 13.2 (6.0–28.7)
p-Value 0.012
UCP2  866G.AG G 58 (44.3) 784 (37.6) GG þ FPG þ BMI 10 (34.5) 58 (8.1)
GA/AA 73 (55.7) 1,301 (62.4) GA/AA þ none 19 (65.5) 660 (91.9)
HR (95% CI) 1.4 (1.0–1.9) 4.8 (2.1–11.1)
p-Value 0.049
IRS1 G972R GG 108 (82.4) 1,758 (85.9) GR/RR þ FPG þ BMI 7 (21.2) 18 (2)
GR/RR 23 (17.6) 289 (14.1) GG þ none 26 (78.8) 874 (98)
HR (95% CI) 1.3 (0.8–2.1) 9.3 (3.6–23.9)
p-Value 0.28
KCNJ11 E23K EE 34 (26.2) 496 (23.5) EK/KK þ FPG þ BMI 11 (31.4) 252 (72)
EK/KK 96 (73.8) 1,611 (76.5) EE þ none 24 (68.6) 98 (28)
HR (95% CI) 0.7 (0.5–1.1) 2.9 (1.4–6.0)
p-Value 0.13
PPARG/CAPN10 SNP44 PP/TT 74 (56.9) 954 (45.2) PP/TT þ FPG þ BMI 23 (59.0) 53 (8.8)
Other 56 (43.1) 1,155 (54.8) Other þ none 16 (41.0) 549 (91.2)
HR (95% CI) 2.6 (1.5–4.5) 14.4 (6.5–32.3)
p-Value 0.001
PPARG/CAPN10 SNP43/44 PP/GG/TT 40 (31.5) 374 (18.2) PP/GG/TT þ FPG þ BMI 17 (40.5) 21 (2.5)
Other 87 (68.5) 1,685 (81.8) Other þ none 25 (59.5) 815 (97.5)
HR (95% CI) 3.3 (1.7–6.8) 21.2 (8.7–51.4)
p-Value 0.001
— — — FPG þ BMI 30 (48.4) 130 (11)
None 32 (51.6) 1,057 (89)
HR (95% CI) 6 (3.7–10.0)
HRs are from age-adjusted COX proportional hazard regression analyses stratified on sex and adjusted for family history of diabetes and BMI (univariate effects).
aAll multivariate effects are significant at p , 0.001.
DOI: 10.1371/journal.pmed.0020345.t003
PLoS Medicine | www.plosmedicine.org December 2005 | Volume 2 | Issue 12 | e345 1303
Prediction of Type 2 Diabeteswas also more frequent among patients with earlier than late
onset of T2D (60.3% versus 39.7%, p¼0.042; v
2 test and odds
ratio 2.5, 95% CI 1.2–5.3, p¼0.016; logistic regression analyses
adjustedforgender,BMI,andfamilyhistoryofdiabetes).None
of the other tested genotypes predicted signiﬁcantly earlier
onset of T2D.
IRS1
Twenty-three (17.6%) converters carried the RR/RG geno-
types of the IRS1 G972R polymorphism. Whereas the R allele
had no independent effect on T2D risk, it increased the risk of
T2D in a dominant fashion (RR or RG versus GG) in
participants with elevated FPG and BMI   30 kg/m
2 to 9.3
(95% CI 3.6–23.9, p , 0.001) (see Table 3).
KCNJ11
Ninety-six converters (73.8%) had the risk EK/KK genotypes
of the KCNJ11 E23K polymorphism, but these genotypes did
not increase risk of future T2D, neither alone nor in
combination with elevated FPG or high BMI. In line with
previous ﬁndings of an effect of this variant on insulin
secretion [16–18], there was a signiﬁcant interaction between
theKCNJ11E23Kpolymorphismandthedispositionindex(p,
0.001), suggesting that the risk of T2D associated with a low
disposition index [31] is increased by the EK/KK genotypes.
Combined Genetic Effects
In total, 1,028 (45.9%) individuals carried risk genotypes in
both PPARG (PP) and CAPN10 SNP44 (TT), whereas 397
(18.2%) individuals had three risk genotypes: PPARG (PP),
CAPN10(TT),andUCP2(GG).TheeffectofboththePPARGPP
and CAPN10 SNP44 TT genotypes on the risk of subsequent
T2D when present in the same individual was greater (HR 2.6,
95% CI 1.5–4.5) than the individual risks (Table 3). The effect
was even stronger when the combination of at-risk GG and TT
genotypes of both SNP43 and 44 of the CAPN10 gene (HR 3.3,
95% CI 1.7–6.8) (Table 3; see Figure 1) was included in the
analysis. Again, the incidence of T2D in participants with the
combinationofSNP43(GG)andSNP44(TT)inCAPN10,thePP
Figure 2. The Effects of Risk Genotypes of the PPARG P12A Poly-
morphism (PP), the Combination of CAPN10 SNP43/44 (GG/TT), and the
Combination of PPARG and CAPN10 SNP43/44 (PP/GG/TT) Together with
FPG and BMI for the Risk of Developing T2D
y-Axis denotes incident diabetes estimated as the proportion (percent) of
participants who developed diabetes during the follow-up period in the
groups with each risk factor defined as risk genotype, elevated FPG ( 5.6
mmol/l), and high BMI ( 30 kg/m
2). The absolute number of individuals
who developed diabetes in the groups with each risk factor is given
within the bars (in parentheses) and in Table S2. The incidence of T2D
was significantly increased in carriers of the risk PP genotype, GG/TT
genotypes, and PP/GG/TT genotypes with elevated FPG and high BMI as
compared with individuals carrying low risk genotypes without risk
factors (v
2 test, p , 0.001).
DOI: 10.1371/journal.pmed.0020345.g002
Figure 3. The Effect of Insulin Resistance Together with the Risk
Genotype of the PPARG P12A Polymorphism on Risk of Developing T2D
y-Axis denotes HR and its 95% CI. x-Axis denotes increase in insulin
resistance estimated as HOMAIR.
DOI: 10.1371/journal.pmed.0020345.g003
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Prediction of Type 2 Diabetesgenotype in the PPARG gene, elevated FPG, and high BMI was
markedly higher than in those with low risk genotypes and no
other risk factors (44.7% versus 3.0%, p , 0.001) (see Figure 2),
with a HR of 21.2 (95% CI 8.7–51.4, p , 0.001) (Table 3). Also,
these combinations inﬂuenced the correlation between BMI
and FPG, yielding a steeper increase in FPG for any increase in
BMI in carriers of the risk genotype combinations than in
carriers of the non-risk genotypes (0.28 versus 0.19, p¼0.041).
Discussion
The key ﬁnding of the present study was that variants in the
PPARG and CAPN10 genes increased the future risk for T2D,
particularly in individuals with other risk factors. A question
often raised about genetic association studies of polygenic
diseases is whether the information can be used to predict the
disease, since the risk conferred by the variant is usually rather
modest (odds ratio , 1.2–1.3) [6]. In T2D association studies,
cases are usually ascertained through diabetes clinics and
thereby possibly enriched by carriers of more severe genetic
variants. It was therefore encouraging to see that polymor-
phisms in some genes previously shown to be associated with
T2D in case-control studies (particularly P12A in PPARG and
SNP44 in CAPN10) [4,15] could predict T2D in high risk
individuals from families with T2D.
The relative risk (ks) of developing T2D for members of the
Botnia families is about three. However, this risk is greatest in
obese (BMI   30 kg/m
2) individuals with FPG above normal
( 5.6 mmol/l) and a family history of T2D [31]. Replacing the
family history with the PPARG and CAPN10 variants, and
particularly with their combination, gave almost the same
strong prediction of subsequent T2D. These genotypes also
inﬂuenced the relationship between BMI and FPG, i.e., in
carriers of the risk genotypes there was a steeper increase in
FPG for any given increase in BMI.
Several papers have examined the effect of single gene
variants on the risk of conversion to T2D in interventional
trials like the Finnish Diabetes Prevention Study [9,17] and the
STOP-NIDDM trial [11]. However, it is important to know the
effect of these genetic variants on risk of future T2D in an
observational study before conclusions can be drawn on their
putativeadditiveorsynergisticeffects,togetherwiththeeffects
of speciﬁc factors such life style changes [9,17] or acarbose use
[11]. Many of these studies have provided conﬂicting results in
different subgroups; this is a natural corollary of their design,
which breaks the initial cohorts down in relatively small
subgroupswith limitedpower.Although thepresent study also
has limited power, it is to our knowledge the largest of its kind,
and it also provides information on key T2D variants in the
same paper.
PPARG
The P12A polymorphism in PPARG is to date the best
replicated genetic variant for T2D, with a cumulative odds
ratiofrompublishedstudiesofabout1.25andoverallp,0.001
[4,8]. The P12A variant is located in an extra exon B in the 59-
end of the adipose-speciﬁc PPARG2i s o f o r ma n ds h o w s
reduced transcription of target genes. The A allele has been
associated with increased insulin sensitivity [35], particularly,
enhancedsuppressionof lipolysis[36]. Insupportofthis,there
was a signiﬁcant interaction between the P12A polymorphism
and HOMAIR (which measures insulin resistance). The Nurse’s
Health Study also reported reduced risk for developing
diabetes in carriers of the A allele [10]. Most recently, the
STOP-NIDDM trial also reported that the PP genotype
predicted conversion to diabetes in women in the acarbose
intervention group [11]. These combined data, however,
contrast with ﬁndings in the Finnish Diabetes Prevention
Study,whichreportedanincreasedriskofdevelopingdiabetes
incarriersoftheAallelecomparedtoindividualswiththeP12P
genotype [9]. This effect was restricted to the control group,
whereas the few A12A carriers in the intervention group lost
more weight than the P12P carriers. As enhanced insulin
sensitivity is a risk factor for weight gain, the A allele has also
been associated with more rapid weight regain after weight
reduction[37].Itisthereforepossiblethattheprotectiveeffect
of the A allele is attenuated in very obese individuals.
Differences in BMI cannot fully explain the different results,
since the risk conferred by the P12P genotype was maintained
after adjusting for BMI in the present study. The effect of the
P12A variant on BMI and lipolysis is also dependent upon
intake of saturated fat [38]. Taken together, the data suggest a
complex interaction between the P12A polymorphism in the
PPARG gene and diet, body weight, and insulin sensitivity in
predicting risk of future T2D.
Notably, the HR in the present prospective study was higher
than the odds ratios in previous case-control studies [4]. The
same also applies to the odds ratios obtained in the
intervention studies discussed [10,11]. Although there could
be several possible explanations for this discrepancy, a likely
explanationistheaccuracybywhichthecases(converters)and
controls (non-converters) were deﬁned in the prospective
Table 4. Risk of Developing Earlier Onset T2D in Different
Genotype Carriers of the Studied Polymorphisms
Gene Genotype Converters, n (%) Non-Converters, n (%)
PPARG P12A PP 52 (78.8) 1,558 (72.8)
PA/AA 14 (21.2) 583 (27.2)
HR (95% CI) 1.4 (0.7–2.5)
p-Value 0.31
CAPN10 SNP43G.A GG 35 (54.7) 1,046 (50.0)
GA/AA 29 (45.3) 1,044 (50.0)
HR (95% CI) 0.5 (0.8–2.2)
p-Value 0.32
CAPN10 SNP44T.C TT 44 (68.8) 1,309 (61.6)
TC/CC 20 (31.2) 816 (38.4)
HR (95% CI) 1.4 (0.8–2.4)
p-Value 0.25
UCP2  866G.AG G 35 (53.0) 784 (37.6)
GA/AA 31 (47.0) 1,301 (62.4)
HR (95% CI) 2.0 (1.2–3.3)
p-Value 0.0057
IRS1 G972R GG 52 (80.0) 1,758 (95.9)
GR/RR 13 (20.0) 289 (14.1)
HR (95% CI) 1.9 (1.0–3.4)
p-Value 0.049
KCNJ11 E23K EE 19 (29.2) 496 (23.5)
EK/KK 46 (70.8) 1,611 (76.5)
HR (95% CI) 0.7 (0.4–1.2)
p-Value 0.20
HRs are from age-adjusted COX proportional hazard regression analyses stratified on sex and adjusted for BMI and
family history of diabetes. The earlier onset T2D was defined using the median (58 y) of the age of onset. The mean
(6 standard deviation) age at diagnosis of the subgroup below the median was 46 6 10 y compared with 67 6 7y
for those above the median.
DOI: 10.1371/journal.pmed.0020345.t004
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Prediction of Type 2 Diabetesstudy ascompared with a case-control association study.In the
prospective study all individuals underwent repeated OGTTs
todeﬁne glucose tolerance status, whilein case-control studies
the deﬁnition of normal glucose tolerance is often based upon
one OGTT. Therefore, we assume that we have a certain
proportion of controls misclassiﬁed. We simulated (1,000
times) this situation by introducing 5%, 10%, and 20%
misclassiﬁcation of non-converters regarding the HR of 1.72
for the P12A polymorphism in the PPARG gene to predict
future diabetes. A 5% misclassiﬁcation would result in a
decreaseinHRto1.31(minimum0.85;maximum1.97),10%to
1.18 (minimum 0.84; maximum 1.68), and 20% to 1.08
(minimum 0.82; maximum 1.38). Of course, there also could
be other factors contributing, such as change in diabetes
prevalence (which almost doubled) between the time when the
cases in the case-control study and the converters in the
prospective study were diagnosed. Finally, our study was
carried out in a high risk population of ﬁrst degree relatives
of patients with T2D.
CAPN10
The discovery that intronic SNPs in the CAPN10 gene
explained the linkage to Chromosome 2q in Mexican-Amer-
icans represented the ﬁrst successful positional cloning of a
T2D gene [12]. It also raised a number of questions, e.g., how
couldtheseintronicSNPsinageneencodingacysteinprotease
confer increased risk of T2D? Several recent meta-analyses
have demonstrated a consistent but modest risk of SNP43 and
44(oddsratio1.15–1.20)fortheassociationwithT2D[13,14].In
opposite direction to other studies [13,14], in the Botnia study
the TT genotype of SNP44 has been associated with increased
risk of T2D [15]. However, a stronger association was seen for
thecombinationofboththeGGgenotypeofSNP43andtheTT
genotype of SNP44 [15]. Carriers of the GG genotype of SNP43
have decreased CAPN10 mRNA levels in skeletal muscle, which
correlates with more severe insulin resistance [39]. Our data of
an interaction between HOMAIR and the CAPN10 SNP43
s u p p o r t st h i sn o t i o n .T h eq u e s t i o na r i s e sw h e t h e rt h e
combined effect of variants in the PPPARG and CAPN10 genes
on risk for future T2D can be solely explained by the variants’
effectoninsulinsensitivity.Acombinedeffectofthetwogenes
on both insulin secretion and action would be more plausible.
However, the knowledge of molecular mechanisms by which
calpain 10 would increase susceptibility to T2D is limited.
UCP2
Impaired insulin secretion has been shown to predominate
overinsulin resistance inindividuals with earlyonset T2D [40].
Inlinewiththisview,theUCP2variantwasastrongpredictorof
T2Dwithearlieronset.ThepromotervariantintheUCP2gene
has been associated with increased expression of the gene in
adipose tissue [41]. If this variant is associated with increased
UCP2 mRNA levels in human pancreatic b-cells (which is not
known), this could result in increased uncoupling and, in turn,
indecreasedformationofATPandimpairedinsulinsecretion.
KCNJ11
Genetic variants in the KCNJ11 gene have not only been
associated with T2D [16,18], but also with a severe form of
neonatal diabetes [42]. Whereas these neonatal mutations
result in a 10-fold activation of the ATP-dependent potassium
channel, the E23K variant results in only a 2-fold increase in
activity [43]. The KCNJ11 E23K variant did not signiﬁcantly
increase the risk for T2D in our study’s participants. We have
no explanation for this ﬁnding other than lack of power (the
study had only 52% power to detect an effect of KCNJ11 E23K
on risk of developing T2D) or the presence of other
unidentiﬁed risk factors in the patients with manifest T2D.
Wedid,however,observeaninteractionbetweentheEKand/or
KK genotypes and impaired b-cell function, supporting a role
in insulin secretion.
Conclusion
In conclusion, we show in a large observational prospective
study that genetic variants in candidate genes can predict
future T2D, particularly in association with conventional risk
factors such as obesity and abnormal glucose tolerance. With
accumulating data from prospective studies, it should be
possible to deﬁne whether there will be a future role for these
variants in genetic prediction of T2D and whether these
variants will inﬂuence response to prevention or treatment.
Although this study is, to our knowledge, the largest of its
kindthusfar,itstillhaslimitedpowertodetectaneffectoflow-
frequencyalleles.Itisthereforeobviousthatlargerstudieswith
longerfollow-upareneededtoreplicatetheﬁndings.Onesuch
resource will be the Malmo ¨ Diabetes Prevention cohort, in
which 22,000 individuals have been followed for more than 20
y. They are presently being restudied to obtain DNA and
information on whether they have developed diabetes or not.
While waiting for these results, it will be important to create
consortia to merge data from available prospective studies.
Supporting Information
Table S1. Primers and Probes Used in the Study
Found at DOI: 10.1371/journal.pmed.0020345.st001 (92 KB PDF).
Table S2. The Number of Individuals Who Developed T2D Carrying
Different Risk Factors
Found at DOI: 10.1371/journal.pmed.0020345.st002 (93 KB PDF).
Accession Numbers
The NCBI Entrez (http://www.ncbi.nlm.nih.gov/gquery/
gquery.fcgi) accession numbers for the polymorphisms dis-
cussed in this paper are CAPN10 SNP43 (rs3792267), CAPN10
SNP44 (rs2975760), IRS1 G972R (rs1801278), KCNJ11 E23K
(rs5219), PPARG P12A (rs1801282), and UCP2  866G.A
(rs659366).
Acknowledgments
ThisworkwassupportedbygrantsfromtheSigridJuseliusFoundation,
EuropeanCommunity(GenomicIntegratedForceforType2Diabetes,
grant QLG2-Ct-1999–0546), Folkha ¨lsan Research Foundation, the
Swedish Research Council, Academy of Finland, the Lundberg
Foundation, the Novo Nordic Foundation, the European Federation
for the Study of Diabetes (Sankyo Pharma), the Diabetes Research
Foundation, the Albert Pa ˚hlssons Foundation, Crafoord Foundation,
and the Anna-Lisa and Sven-Eric Lundgren Foundation. We thank the
patientsfortheirparticipationandtheBotniaresearchteam,aswellas
Malin Svensson and Barbro Gustavsson for excellent technical
assistance. The funders had no role in study design, data collection
and analysis, decision to publish, or preparation of the manuscript.
The Botnia Study Group
Investigator from Vasa, Finland: Mikael Nisse ´n.
Investigators from Jakobstads Health Center, Jakobstads Hospital,
and Folkhalsan O ¨ stanlid, Jakobstad, Finland: Bo Isomaa, Leena
Sarelin, and Carola Svenfelt.
Investigators from Korsholms Health Center, Korsholm, Finland:
Ulla-Britt Bjo ¨rk, Nils Holmstro ¨m, and Jessica Strand.
PLoS Medicine | www.plosmedicine.org December 2005 | Volume 2 | Issue 12 | e345 1306
Prediction of Type 2 DiabetesInvestigators from Malax Health Center, Malax, Finland: Lisbeth
A ˚ kerman and Inga-Britt Stenback.
Investigators from Na ¨rpes Health Center, Na ¨rpes, Finland: Bjo ¨rn
Forse ´n, Monika Gullstro ¨m, Maja Ha ¨ggblom, and Susann So ¨derback.
Investigators from Vasa Health Center, Vasa, Finland: Kaj Lahti,
Marianne Nyman, and Sonja Paulaharju.
Investigators from Department of Medicine, Helsinki University
Central Hospital; Folkhalsan Research Center, Department of
Genetics, and Research Program fo ¨r Molecular Medicine, University
of Helsinki, Helsinki, Finland: Seija Heikkinen, Paula Kokko, Merja
Lahtinen, Mikko Lehtovirta, and Virve Lundgren.
Investigators from Department of Medicine, Helsinki University
Central Hospital; Research Program for Cardiovascular Diseases,
University of Helsinki, Helsinki, Finland: Hannele Hilde ´n and Marja-
Riitta Taskinen.
Investigators from Department of Clinical Sciences, Diabetes, and
Endocrinology, Lund University, Malmo ¨ University Hospital, Malmo ¨,
Sweden: Esa Laurila and Margareta Svensson. &
References
1. Zimmet P, Alberti KG, Shaw J (2001) Global and societal implications of the
diabetes epidemic. Nature 414: 782–787.
2. Bonadonna RC (2004) Alterations of glucose metabolism in type 2 diabetes
mellitus. An overview. Rev Endocr Metab Disord 5: 89–97.
3. Chan JM, Rimm EB, Colditz GA, Stampfer MJ, Willett WC (1994) Obesity,
fat distribution, and weight gain as risk factors for clinical diabetes in men.
Diabetes Care 17: 961–969.
4. Altshuler D, Hirschhorn JN, Klannemark M, Lindgren CM, Vohl MC, et al.
(2000) The common PPARgamma Pro12Ala polymorphism is associated
with decreased risk of type 2 diabetes. Nat Genet 26: 76–80.
5. Barroso I, Luan J, Middelberg RP, Harding AH, Franks PW, et al. (2003)
Candidate gene association study in type 2 diabetes indicates a role for
genes involved in b-cell function as well as insulin action. PLoS Biol 1: e20.
DOI: 10.1371/journal.pbio.0000020
6. Florez JC, Hirschhorn J, Altshuler D (2003) The inherited basis of diabetes
mellitus: Implications for the genetic analysis of complex traits. Annu Rev
Genomics Hum Genet 4: 257–291.
7. Laukkanen O, Pihlajamaki J, Lindstrom J, Eriksson J, Valle TT, et al. (2004)
Common polymorphisms in the genes regulating the early insulin signal-
ling pathway: Effects on weight change and the conversion from impaired
glucose tolerance to type 2 diabetes. The Finnish Diabetes Prevention
Study. Diabetologia 47: 871–877.
8. Parikh H, Groop L (2004) Candidate genes for type 2 diabetes. Rev Endocr
Metab Disord 5: 151–176.
9. Lindi VI, Uusitupa MI, Lindstrom J, Louheranta A, Eriksson JG, et al. (2002)
Association of the Pro12Ala polymorphism in the PPAR-gamma2 gene with
3-year incidence of type 2 diabetes and body weight change in the Finnish
Diabetes Prevention Study. Diabetes 51: 2581–2586.
10. Memisoglu A, Hu FB, Hankinson SE, Liu S, Meigs JB, et al. (2003)
Prospective study of the association between the proline to alanine codon
12 polymorphism in the PPARgamma gene and type 2 diabetes. Diabetes
Care 16: 2915–2917.
11. Andrulionyte L, Zacharova J, Chiasson JL, Laakso M (2004) Common
polymorphisms of the PPAR-gamma2 (Pro12Ala) and PGC-1alpha
(Gly482Ser) genes are associated with the conversion from impaired
glucose tolerance to type 2 diabetes in the STOP-NIDDM trial. Diabeto-
logia 47: 2176–2184.
12. Horikawa Y, Oda N, Cox NJ, Li X, Orho-Melander M, et al. (2000) Genetic
variation in the gene encoding calpain-10 is associated with type 2 diabetes
mellitus. Nat Genet 26: 163–175.
13. Weedon MN, Schwarz PE, Horikawa Y, Iwasaki N, Illig T, et al. (2003) Meta-
analysis and a large association study conﬁrm a role for calpain-10
variation in type 2 diabetes susceptibility. Am J Hum Genet 73: 1208–1212.
14. MSong Y, Niu T, Manson JE, Kwiatkowski DJ, Liu S (2004) Are variants in the
CAPN10 gene related to risk of type 2 diabetes? A quantitative assessment of
populationandfamily-basedassociationstudies.AmJHumGenet74:208–222.
15. Orho-Melander M, Klannemark M, Svensson MK, Ridderstrale M, Lindgren
CM, et al. (2002) Variants in the calpain-10 gene predispose to insulin
resistance and elevated free fatty acid levels. Diabetes 51: 2658–2664.
16. Gloyn AL, Weedon MN, Owen KR, Turner MJ, Knight BA, et al. (2003)
Large-scale association studies of variants in genes encoding the pancreatic
beta-cell KATP channel subunits Kir6.2 (KCNJ11) and SUR1 (ABCC8)
conﬁrm that the KCNJ11 E23K variant is associated with type 2 diabetes.
Diabetes 52: 568–572.
17. Laukkanen O, Pihlajamaki J, Lindstrom J, Eriksson J, Valle TT, et al. (2004)
Polymorphisms of the SUR1 (ABCC8) and Kir6.2 (KCNJ11) genes predict
the conversion from impaired glucose tolerance to type 2 diabetes. The
Finnish Diabetes Prevention Study. J Clin Endocrinol Metab 89: 6286–6290.
18. Florez JC, Burtt N, De Bakker PI, Almgren P, Tuomi T, et al. (2004)
Haplotype structure and genotype-phenotype correlations of the sulfony-
lurea receptor and the islet ATP-sensitive potassium channel gene region.
Diabetes 53: 1360–1368.
19. Marchetti P, Lupi R, Federici M, Marselli L, Masini M, et al. (2002) Insulin
secretory function is impaired in isolated human islets carrying the
Gly(972)!Arg IRS-1 polymorphism. Diabetes 51: 1419–1424.
20. Jellema A, Zeegers MP, Feskens EJ, Dagnelie PC, Mensink RP (2003)
Gly972Arg variant in the insulin receptor substrate-1 gene and association
with type 2 diabetes: A meta-analysis of 27 studies. Diabetologia 46: 990–995.
21. Zeggini E, Parkinson J, Halford S, Owen KR, Frayling TM, et al. (2004)
Association studies of insulin receptor substrate 1 gene (IRS1) variants in
type 2 diabetes samples enriched for family history and early age of onset.
Diabetes 53: 3319–3322.
22. Florez JC, Sjogren M, Burtt N, Orho-Melander M, Schayer S, et al. (2004)
Association testing in 9,000 people fails to conﬁrm the association of the
insulin receptor substrate-1 G972R polymorphism with type 2 diabetes.
Diabetes 53: 3313–3318.
23. van Dam RM, Hoebee B, Seidell JC, Schaap MM, Blaak EE, et al. (2004) The
insulin receptor substrate-1 Gly972Arg polymorphism is not associated
with type 2 diabetes mellitus in two population-based studies. Diabet Med
21: 752–758.
24. Wang H, Chu WS, Lu T, Hasstedt SJ, Kern PA, et al. (2004) Uncoupling
protein-2 polymorphisms in type 2 diabetes, obesity, and insulin secretion.
Am J Physiol Endocrinol Metab. 286: E1–E7.
25. Sasahara M, Nishi M, Kawashima H, Ueda K, Sakagashira S, et al. (2004)
Uncoupling protein 2 promoter polymorphism  866G/A affects its
expression in beta-cells and modulates clinical proﬁles of Japanese type 2
diabetic patients. Diabetes 53: 482–485.
26. D’Adamo M, Perego L, Cardellini M, Marini MA, Frontoni S, et al. (2004)
The 866A/A genotype in the promoter of the human uncoupling protein 2
gene is associated with insulin resistance and increased risk of type 2
diabetes. Diabetes 53: 1905–1910.
27. Bulotta A, Ludovico O, Coco A, Di Paola R, Quattrone A, et al. (2005) The
common 866G/A polymorphism in the promoter region of the UCP2 gene
is associated with reduced risk of type 2 diabetes in Caucasians from Italy. J
Clin Endocrinol Metab 90: 1176–1180.
28. Krempler F, Esterbauer H, Weitgasser R, Ebenbichler C, Patsch JR, et al.
(2002) A functional polymorphism in the promoter of UCP2 enhances
obesity risk but reduces type 2 diabetes risk in obese middle-aged humans.
Diabetes 51: 3331–3335.
29. Chan CB, De Leo D, Joseph JW, McQuaid TS, Ha XF, et al. (2001) Increased
uncouplingprotein-2levelsinbeta-cellsareassociatedwithimpairedglucose-
stimulated insulin secretion: Mechanism of action. Diabetes 50: 1302–1310.
30. Groop L, Forsblom C, Lehtovirta M, Tuomi T, Karanko S, et al. (1996)
Metabolic consequences of a family history of NIDDM (the Botnia study):
Evidence for sex-speciﬁc parental effects. Diabetes 45: 1585–1593.
31. Lyssenko V, Almgren P, Anevski D, Perfekt R, Lahti K, et al. (2005)
Predictors of and longitudinal changes in insulin sensitivity and secretion
preceding onset of type 2 diabetes. Diabetes 54: 166–174.
32. World Health Organization (1999) Deﬁnition, diagnosis, and classiﬁcation
of diabetes mellitus and its complications. Report of a WHO consultation.
Part 1: Diagnosis and classiﬁcation of diabetes mellitus. Geneva: World
Health Organization. Available: http://whqlibdoc.who.int/hq/1999/
WHO_NCD_NCS_99.2.pdf. Accessed 14 September 2005.
33. Levy JC, Matthews DR, Hermans MP (1998) Correct homeostasis model
assessment (HOMA) evaluation uses the computer program. Diabetes Care
21: 2191–2192.
34. Klein JP, Moeschberger ML (2003) Survival analysis: Techniques for
censored and truncated data, 2nd ed. New York: Springer. 536 p.
35. Deeb SS, Fajas L, Nemoto M, Pihlajamaki J, Mykkanen L, et al. (1998) A
Pro12Ala substitution in PPARgamma2 associated with decreased receptor
activity, lower body mass index and improved insulin sensitivity. Nat Genet
20: 284–287.
36. Stumvoll M, Haring H (2002) Reduced lipolysis as possible cause for greater
weight gain in subjects with the Pro12Ala polymorphism in PPARgamma2?
Diabetologia 45: 152–153.
37. Nicklas BJ, van Rossum EF, Berman DM, Ryan AS, Dennis KE, et al. (2001)
Genetic variation in the peroxisome proliferator-activated receptor-
gamma2 gene (Pro12Ala) affects metabolic responses to weight loss and
subsequent weight regain. Diabetes 50: 2172–2176.
38. Luan J, Browne PO, Harding AH, Halsall DJ, O’Rahilly S, et al. (2001)
Evidence for gene-nutrient interaction at the PPARgamma locus. Diabetes
50: 686–689.
39. Baier LJ, Permana PA, Yang X, Pratley RE, Hanson RL, et al. (2000) A
calpain-10 gene polymorphism is associated with reduced muscle mRNA
levels and insulin resistance. J Clin Invest 106: R69–R73.
40. O’Rahilly S, Spivey RS, Holman RR, Nugent Z, Clark A, et al. (1987) Type II
diabetes of early onset: A distinct clinical and genetic syndrome? Br Med J
294: 923–928.
41. Esterbauer H, Schneitler C, Oberkoﬂer H, Ebenbichler C, Paulweber B, et al.
(2001) A common polymorphism in the promoter of UCP2 is associated with
decreased risk of obesity in middle-aged humans. Nat Genet 28: 178–183.
42. Gloyn AL, Pearson ER, Antcliff JF, Proks P, Bruining GJ, et al. (2004)
Activating mutations in the gene encoding the ATP-sensitive potassium-
channel subunit Kir6.2 and permanent neonatal diabetes. N Engl J Med
350: 1838–1849.
43. Nichols CG, Koster JC (2002) Diabetes and insulin secretion: Whither
KATP? Am J Physiol Endocrinol Metab 283: E403–E412.
PLoS Medicine | www.plosmedicine.org December 2005 | Volume 2 | Issue 12 | e345 1307
Prediction of Type 2 DiabetesPatient Summary
Background Type 2 diabetes, also known as adult onset or non-insulin-
dependent diabetes, is increasing in frequency around the world. Many
different factors work together to make someone more likely to develop
diabetes, including factors in their environment—for example, the food
they eat—and in their family background—the genes they inherited
from their parents. Many studies have been done looking at which genes
are associated with diabetes, but few have tried to see whether it is
possible to predict who will get diabetes in future from looking at a
person’s genes before any symptoms develop.
Why Was This Study Done? These authors wanted to look at changes in
five genes previously shown to be associated with diabetes in a group of
people who were to be followed prospectively—that is, from before they
developed diabetes—and see if it was possible to predict who would get
diabetes.
What Did the Researchers Do and Find? They studied 2,293 people in
Finland who were family members or spouses of people with type 2
diabetes, but who themselves did not have diabetes. They followed
these people for up to 12 years, starting in 1990. In total, 132 of these
individuals (6%) developed diabetes during this time. They found that
changes in two of the genes, PPARG (which is involved in how the body
regulates fat tissue) and CAPN10 (which is involved in modifying certain
proteins), were associated with people having a higher chance of getting
type 2 diabetes. This chance was increased substantially when the
participants already had slightly raised blood glucose, and a high body
mass index.
What Do These Findings Mean? In some people, it does seem possible
to use certain genes to predict whether a person will develop type 2
diabetes. However, environmental factors are also very important, and
any risk is much increased in people who are already overweight.
Where Can I Get More Information Online? MedlinePlus has many
links to pages of information on diabetes:
http://www.nlm.nih.gov/medlineplus/ency/article/001214.htm
The Finnish Diabetes Association has information on diabetes in general
and more specifically for Finland:
http://www.diabetes.fi/english/
PLoS Medicine | www.plosmedicine.org December 2005 | Volume 2 | Issue 12 | e345 1308
Prediction of Type 2 Diabetes